Peter James O'Dwyer
ECOG-ACRIN Cancer Research Group · 822 works · 43,318 citations · h-index 89
Top works
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
- Etoposide (VP-16–213)
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
- Combined-Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver: Surgical Resection of Hepatic Metastases in Combination With Continuous Infusion of Chemotherapy--An Intergroup Study
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
- Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
- Mechanisms of Hypertension Associated With BAY 43-9006
- Gene Expression Patterns in Ovarian Carcinomas
- Activation of AP-1 and of a Nuclear Redox Factor, Ref-1, in the Response of HT29 Colon Cancer Cells to Hypoxia
- Phase I Clinical Trial Design in Cancer Drug Development